Prospective evaluation of standard chemotherapy regimen of idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML).

Trial Profile

Prospective evaluation of standard chemotherapy regimen of idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Cytarabine (Primary) ; Idarubicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 10 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top